Kissei Pharmaceutical Co., Ltd.
4547.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.25 | 1.75 | -0.62 | 0.06 |
| FCF Yield | 1.20% | -2.24% | -7.58% | -0.33% |
| EV / EBITDA | 7.10 | 7.23 | 5.47 | 4.41 |
| Quality | ||||
| ROIC | 1.94% | 1.28% | -0.42% | -0.50% |
| Gross Margin | 49.89% | 49.41% | 47.97% | 47.78% |
| Cash Conversion Ratio | 0.55 | -0.15 | -0.49 | 0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.38% | 4.95% | -0.75% | 1.11% |
| Free Cash Flow Growth | 157.38% | 61.96% | -2,290.16% | 90.41% |
| Safety | ||||
| Net Debt / EBITDA | -1.18 | -1.15 | -1.37 | -1.40 |
| Interest Coverage | 274.95 | 223.17 | -56.45 | -60.96 |
| Efficiency | ||||
| Inventory Turnover | 1.77 | 1.45 | 1.54 | 1.80 |
| Cash Conversion Cycle | 290.56 | 342.80 | 312.30 | 286.42 |